Ginsenosides for the treatment of metabolic syndrome and cardiovascular diseases: Pharmacology and mechanisms

Abstract

Epidemiological studies showed that the metabolic syndromes (MetS) and cardiovascular diseases (CVDs) are responsible for a serious threat to human health worldwide. MetS is a syndromes characterized by fat metabolism disorder, obesity, diabetes, insulin resistance and other risk factors, which increases the risk of CVDs initiation and development. Although certain drugs play a role in lowering blood sugar and lipid, some side effects also occur. Considering the multiple pathogenesis, a great deal of natural products have been attempted to treat metabolic syndromes. Ginsenosides, as the active components isolated from Panax ginseng C.A.Mey, have been reported to have therapeutic effects on MetS and CVDs, of which pharmacological mechanisms were further studied as well. This review aims to systematically summarize current pharmacological effects of ginsenosides on MetS and CVDs, potential mechanisms and clinic trials, which will greatly contribute to the development of potential agents for related disease treatment.

Keywords: Cardiovascular diseases; Ginsenoside Rb1 (PubChem CID:9898279); Ginsenoside Rb2 (PubChem CID: 6917976); Ginsenoside Rb3 (PubChem CID: 12912363); Ginsenoside Rd (PubChem CID:24721561); Ginsenoside Re (PubChem CID: 441921); Ginsenoside Rg1 (PubChem CID:441923); Ginsenoside Rg2 (PubChem CID: 21599924); Ginsenoside Rg3 (PubChem CID: 9918693); Ginsenoside compound K (PubChem CID: 9852086); Ginsenosides; Mechanism; Metabolic syndrome; Signaling pathways.